The DOI matches its Crossref record.
Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure
Abstract
Background—: Therapy for chronic systolic heart failure (sHF) has improved over the past 2 decades, but the armamentarium of drugs is limited and consequently sHF remains a leading cause of death and disability. In this investigation, we examined the effects of a novel cardiac myosin activator, omecamtiv mecarbil (formerly CK-1827452) in 2 different models of heart failure. Methods and Results—: Two different models of sHF were used: (1) pacing-induced sHF after myocardial infarction (MI-sHF) and (2) pacing-induced sHF after 1 year of chronic pressure overload left ventricular hypertrophy (LVH-sHF). Omecamtiv mecarbil increased systolic function in sHF dogs, chronically instrumented to measure LV pressure, wall thickness, and cardiac output. Omecamtiv mecarbil, infused for 24 hours, induced a sustained increase without desensitization ( P <0.05) in wall thickening (25±6.2%), stroke volume (44±6.5%) and cardiac output (22±2.8%), and decreased heart rate (15±3.0%). The major differences between the effect of omecamtiv mecarbil on cardiac function and the effect induced by a catecholamine, for example, dobutamine, is that omecamtiv mecarbil did not increase LV dP/dt but rather increased LV systolic ejection time by 26±2.9% in sHF. Another key difference is that myocardial O 2 consumption (MVO 2 ), which increases with catecholamines, was not significantly affected by omecamtiv mecarbil. Conclusions—: These results demonstrate that chronic infusion of the cardiac myosin activator, omecamtiv mecarbil, improves LV function in sHF without the limitations of progressive desensitization and increased MVO 2. This unique profile may provide a new therapeutic approach for patients with sHF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2025797 · Cited by 656
Self-citationCardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Malik, F. I., Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., et al. (2011) · Science · doi:10.1126/science.1200113 · Cited by 584
Self-citationCleland, J. G., Teerlink, J. R., Senior, R., Nifontov, E. M., Mc Murray, J. J., Lang, C. C., Tsyrlin, V. A., Greenberg, B. H., Mayet, J., Francis, D. P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61126-4 · Cited by 333
Self-citationTeerlink, J. R., Felker, G. M., McMurray, J. J. V., Solomon, S. D., Adams, K. F., Cleland, J. G. F., Ezekowitz, J. A., Goudev, A., Macdonald, P., Metra, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32049-9 · Cited by 290
Self-citationTeerlink, J. R., Clarke, C. P., Saikali, K. G., Lee, J. H., Chen, M. M., Escandon, R. D., Elliott, L., Bee, R., Habibzadeh, M. R., Goldman, J. H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61219-1 · Cited by 262
Self-citation
Metadata
- Authors
- Shen, Y.-T., Malik, F. I., Zhao, X., Depre, C., Dhar, S. K., Abarzúa, P., Morgans, D. J., & Vatner, S. F.
- Venue
- Circulation: Heart Failure
- Published
- 2010-07
- Volume
- 3
- Issue
- 4
- Pages
- 522-527
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2135958771
- Cited by
- 171
- References
- 0
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure. https://app.cochat.ai/papers/10.1161/circheartfailure.109.930321
- The paper
- Shen, Y.-T., Malik, F. I., Zhao, X., Depre, C., Dhar, S. K., Abarzúa, P., Morgans, D. J., & Vatner, S. F. (2010). Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.109.930321
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.